Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants

Robert Mittendorf, James Dambrosia, Peter G. Pryde, Kwang Sun Lee, John G. Gianopoulos, Richard E. Besinger, Paul G. Tomich

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

OBJECTIVE: The purpose of this study was to determine whether the use of antenatal magnesium sulfate prevents adverse outcomes (neonatal intraventricular hemorrhage, periventricular leucomalacia, death, and cerebral palsy). STUDY DESIGN: In a controlled trial, we randomized mothers in preterm labor to magnesium sulfate, "other" tocolytic, or placebo. At delivery, umbilical cord blood was collected for the later determination of serum ionized magnesium levels. Neonatal cranial ultrasound scans were obtained periodically for the diagnosis of intraventricular hemorrhage and periventricular leucomalacia. Among survivors, the diagnosis of cerebral palsy was made at age 18 months. RESULTS: Children with adverse outcomes had higher umbilical cord magnesium levels at delivery. In regression models that controlled for confounders, which included very low birth weight, magnesium remained a significant risk factor (adjusted odds ratio, 3.7; 95% Cl, 1.1-11.9; P = .03). CONCLUSION: Contrary to original hypotheses, this randomized trial found that the use of antenatal magnesium sulfate was associated with worse, not better, perinatal outcome in a dose-response fashion.

Original languageEnglish (US)
Pages (from-to)1111-1118
Number of pages8
JournalAmerican Journal of Obstetrics and Gynecology
Volume186
Issue number6
DOIs
StatePublished - Jan 1 2002

Fingerprint

Magnesium Sulfate
Premature Obstetric Labor
Magnesium
Periventricular Leukomalacia
Cerebral Palsy
Health
Tocolytic Agents
Hemorrhage
Very Low Birth Weight Infant
Umbilical Cord
Fetal Blood
Survivors
Randomized Controlled Trials
Odds Ratio
Placebos
Mothers
Serum

Keywords

  • Adverse outcomes
  • Magnesium

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. / Mittendorf, Robert; Dambrosia, James; Pryde, Peter G.; Lee, Kwang Sun; Gianopoulos, John G.; Besinger, Richard E.; Tomich, Paul G.

In: American Journal of Obstetrics and Gynecology, Vol. 186, No. 6, 01.01.2002, p. 1111-1118.

Research output: Contribution to journalArticle

Mittendorf, Robert ; Dambrosia, James ; Pryde, Peter G. ; Lee, Kwang Sun ; Gianopoulos, John G. ; Besinger, Richard E. ; Tomich, Paul G. / Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. In: American Journal of Obstetrics and Gynecology. 2002 ; Vol. 186, No. 6. pp. 1111-1118.
@article{902f831291fd419ca8f86932bae16098,
title = "Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants",
abstract = "OBJECTIVE: The purpose of this study was to determine whether the use of antenatal magnesium sulfate prevents adverse outcomes (neonatal intraventricular hemorrhage, periventricular leucomalacia, death, and cerebral palsy). STUDY DESIGN: In a controlled trial, we randomized mothers in preterm labor to magnesium sulfate, {"}other{"} tocolytic, or placebo. At delivery, umbilical cord blood was collected for the later determination of serum ionized magnesium levels. Neonatal cranial ultrasound scans were obtained periodically for the diagnosis of intraventricular hemorrhage and periventricular leucomalacia. Among survivors, the diagnosis of cerebral palsy was made at age 18 months. RESULTS: Children with adverse outcomes had higher umbilical cord magnesium levels at delivery. In regression models that controlled for confounders, which included very low birth weight, magnesium remained a significant risk factor (adjusted odds ratio, 3.7; 95{\%} Cl, 1.1-11.9; P = .03). CONCLUSION: Contrary to original hypotheses, this randomized trial found that the use of antenatal magnesium sulfate was associated with worse, not better, perinatal outcome in a dose-response fashion.",
keywords = "Adverse outcomes, Magnesium",
author = "Robert Mittendorf and James Dambrosia and Pryde, {Peter G.} and Lee, {Kwang Sun} and Gianopoulos, {John G.} and Besinger, {Richard E.} and Tomich, {Paul G.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1067/mob.2002.123544",
language = "English (US)",
volume = "186",
pages = "1111--1118",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants

AU - Mittendorf, Robert

AU - Dambrosia, James

AU - Pryde, Peter G.

AU - Lee, Kwang Sun

AU - Gianopoulos, John G.

AU - Besinger, Richard E.

AU - Tomich, Paul G.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - OBJECTIVE: The purpose of this study was to determine whether the use of antenatal magnesium sulfate prevents adverse outcomes (neonatal intraventricular hemorrhage, periventricular leucomalacia, death, and cerebral palsy). STUDY DESIGN: In a controlled trial, we randomized mothers in preterm labor to magnesium sulfate, "other" tocolytic, or placebo. At delivery, umbilical cord blood was collected for the later determination of serum ionized magnesium levels. Neonatal cranial ultrasound scans were obtained periodically for the diagnosis of intraventricular hemorrhage and periventricular leucomalacia. Among survivors, the diagnosis of cerebral palsy was made at age 18 months. RESULTS: Children with adverse outcomes had higher umbilical cord magnesium levels at delivery. In regression models that controlled for confounders, which included very low birth weight, magnesium remained a significant risk factor (adjusted odds ratio, 3.7; 95% Cl, 1.1-11.9; P = .03). CONCLUSION: Contrary to original hypotheses, this randomized trial found that the use of antenatal magnesium sulfate was associated with worse, not better, perinatal outcome in a dose-response fashion.

AB - OBJECTIVE: The purpose of this study was to determine whether the use of antenatal magnesium sulfate prevents adverse outcomes (neonatal intraventricular hemorrhage, periventricular leucomalacia, death, and cerebral palsy). STUDY DESIGN: In a controlled trial, we randomized mothers in preterm labor to magnesium sulfate, "other" tocolytic, or placebo. At delivery, umbilical cord blood was collected for the later determination of serum ionized magnesium levels. Neonatal cranial ultrasound scans were obtained periodically for the diagnosis of intraventricular hemorrhage and periventricular leucomalacia. Among survivors, the diagnosis of cerebral palsy was made at age 18 months. RESULTS: Children with adverse outcomes had higher umbilical cord magnesium levels at delivery. In regression models that controlled for confounders, which included very low birth weight, magnesium remained a significant risk factor (adjusted odds ratio, 3.7; 95% Cl, 1.1-11.9; P = .03). CONCLUSION: Contrary to original hypotheses, this randomized trial found that the use of antenatal magnesium sulfate was associated with worse, not better, perinatal outcome in a dose-response fashion.

KW - Adverse outcomes

KW - Magnesium

UR - http://www.scopus.com/inward/record.url?scp=0036085123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036085123&partnerID=8YFLogxK

U2 - 10.1067/mob.2002.123544

DO - 10.1067/mob.2002.123544

M3 - Article

C2 - 12066082

AN - SCOPUS:0036085123

VL - 186

SP - 1111

EP - 1118

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -